CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter's five forces analysis

3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.3.6.Market share analysis, 2018

3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in outbreaks of meningococcal disease
3.4.1.2.Surge in immunization programs across the globe
3.4.1.3.Increase in research and development for vaccine technology

3.4.2.Restraint

3.4.2.1.Longer timelines required for vaccine production
3.4.2.2.High costs associated with the development of vaccines

3.4.3.Opportunities

3.4.3.1.Growth opportunities in the emerging markets
3.4.3.2.Increase in healthcare spending
3.4.3.3.Increase in research and development for meningococcal vaccines

3.4.4.Impact analysis

CHAPTER 4:MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.MenACYW Vaccine

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.MenB/BC Vaccine

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.MenC Vaccine

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.MenA Vaccine

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.MenAC Vaccine

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

CHAPTER 5:MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Conjugate Meningococcal Vaccines

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Polysaccharide Vaccine

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Subcapsular Vaccines

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:MENINGOCOCCAL VACCINE MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pediatrics

6.2.1.Market size and forecast
6.2.2.Market analysis, by country

6.3.Adults

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Traveler

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

CHAPTER 7:MENINGOCOCCAL VACCINE MARKET BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. meningococcal vaccine market, by vaccine serotype
7.2.2.1.2.U.S. meningococcal vaccine market, by vaccine type
7.2.2.1.3.U.S. meningococcal vaccine market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada meningococcal vaccine market, by vaccine serotype
7.2.2.2.2.Canada meningococcal vaccine market, by vaccine type
7.2.2.2.3.Canada meningococcal vaccine market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico meningococcal vaccine market, by vaccine serotype
7.2.2.3.2.Mexico meningococcal vaccine market, by vaccine type
7.2.2.3.3.Mexico meningococcal vaccine market, by end user

7.2.3.North America meningococcal vaccine market, by vaccine serotype
7.2.4.North America meningococcal vaccine market, by vaccine type
7.2.5.North America meningococcal vaccine market, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany Meningococcal vaccines market, by Serotype
7.3.2.1.2.Germany Meningococcal vaccines market, by Vaccine type
7.3.2.1.3.Germany Meningococcal vaccines market, by end user

7.3.2.2.France

7.3.2.2.1.France Meningococcal vaccines market, by Serotype
7.3.2.2.2.France Meningococcal vaccines market, by Vaccine type
7.3.2.2.3.France Meningococcal vaccines market, by end user

7.3.2.3.UK

7.3.2.3.1.UK Meningococcal vaccines market, by Serotype
7.3.2.3.2.UK Meningococcal vaccines market, by Vaccine type
7.3.2.3.3.UK Meningococcal vaccines market, by end user

7.3.2.4.The Netherlands

7.3.2.4.1.The Netherlands Meningococcal vaccines market, by Serotype
7.3.2.4.2.The Netherlands Meningococcal vaccines market, by Vaccine type
7.3.2.4.3.The Netherlands Meningococcal vaccines market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain Meningococcal vaccines market, by Serotype
7.3.2.5.2.Spain Meningococcal vaccines market, by Vaccine type
7.3.2.5.3.Spain Meningococcal vaccines market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe Meningococcal vaccines market, by Serotype
7.3.2.6.2.Rest of Europe Meningococcal vaccines market, by Vaccine type
7.3.2.6.3.Rest of Europe Meningococcal vaccines market, by end user

7.3.3.Europe Meningococcal vaccines market, by Serotype
7.3.4.Europe Meningococcal vaccines market, by Vaccine type
7.3.5.Europe Meningococcal vaccines market, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.China

7.4.2.1.1.China meningococcal vaccine market, by vaccine serotype
7.4.2.1.2.China meningococcal vaccine market, by vaccine type
7.4.2.1.3.China meningococcal vaccine market, by end user

7.4.2.2.Australia

7.4.2.2.1.Australia meningococcal vaccine market, by vaccine serotype
7.4.2.2.2.Australia meningococcal vaccine market, by vaccine type
7.4.2.2.3.Australia meningococcal vaccine market, by end user

7.4.2.3.Rest of Asia-Pacific

7.4.2.3.1.Rest of Asia-Pacific meningococcal vaccine market, by vaccine serotype
7.4.2.3.2.Rest of Asia-Pacific meningococcal vaccine market, by vaccine type
7.4.2.3.3.Rest of Asia-Pacific meningococcal vaccine market, by end user

7.4.3.Asia-Pacific meningococcal vaccine market, by vaccine serotype
7.4.4.Asia-Pacific meningococcal vaccine market, by vaccine type
7.4.5.Asia-Pacific meningococcal vaccine market, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Latin America

7.5.2.1.1.Latin America Meningococcal vaccines market, by Serotype
7.5.2.1.2.Latin America Meningococcal vaccines market, by Vaccine type
7.5.2.1.3.Latin America Meningococcal vaccines market, by end user

7.5.2.2.Middle East

7.5.2.2.1.Middle East Meningococcal vaccines market, by Serotype
7.5.2.2.2.Middle East Meningococcal vaccines market, by Vaccine type
7.5.2.2.3.Middle East Meningococcal vaccines market, by end user

7.5.2.3.Africa

7.5.2.3.1.Africa Meningococcal vaccines market, by Serotype
7.5.2.3.2.Africa meningococcal vaccines market, by vaccine type
7.5.2.3.3.Africa meningococcal vaccines market, by end user

7.5.3.LAMEA meningococcal vaccines market, by serotype
7.5.4.LAMEA meningococcal vaccines market, by vaccine type
7.5.5.LAMEA meningococcal vaccines market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.Bio-Manguinhos

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio

8.2.Bio-Med Pvt. Limited

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio

8.3.Chongqing Zhifei Biological Products Co., Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.GlaxoSmithKline Plc

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.1.Key strategic moves and developments

8.5.Hualan Biological Engineering Inc.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio

8.6.Incepta Pharmaceuticals Ltd.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio

8.7.PFIZER INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.SANOFI S.A.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.SERUM INSTITUTE OF INDIA PVT. LTD

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio

8.10.Walvax Biotechnology Co., Ltd.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio